---
title: "NuCana plc (NCNA.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/NCNA.US.md"
symbol: "NCNA.US"
name: "NuCana plc"
industry: "Biotechnology"
datetime: "2026-05-19T10:42:42.369Z"
locales:
  - [en](https://longbridge.com/en/quote/NCNA.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/NCNA.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/NCNA.US.md)
---

# NuCana plc (NCNA.US)

## Company Overview

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer in the United States. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company is developing medicines to overcome the limitations of nucleoside analogs and generate concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer; Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer; and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.nucana.com](https://www.nucana.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.20 | 90 | - | - | - |
| PB | 0.29 | 15 | 0.75 | 0.39 | 0.20 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2025-03-31T04:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Hold | 1 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 2.03 |
| Highest Target | undefined |
| Lowest Target | undefined |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/NCNA.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/NCNA.US/norm.md)
- [Related News](https://longbridge.com/en/quote/NCNA.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/NCNA.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**